Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Depreciation and Depletion (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Depreciation and Depletion for 12 consecutive years, with $4.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation and Depletion fell 6.0% to $4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.5 million, a 0.0% change, with the full-year FY2025 number at $19.5 million, changed 0.0% from a year prior.
  • Depreciation and Depletion was $4.7 million for Q4 2025 at Myriad Genetics, down from $4.8 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $8.7 million in Q1 2023 to a low of $2.6 million in Q3 2021.
  • A 5-year average of $4.1 million and a median of $3.8 million in 2021 define the central range for Depreciation and Depletion.
  • Peak YoY movement for Depreciation and Depletion: skyrocketed 210.71% in 2023, then tumbled 43.68% in 2024.
  • Myriad Genetics' Depreciation and Depletion stood at $3.2 million in 2021, then fell by 3.12% to $3.1 million in 2022, then soared by 38.71% to $4.3 million in 2023, then rose by 16.28% to $5.0 million in 2024, then decreased by 6.0% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Depreciation and Depletion are $4.7 million (Q4 2025), $4.8 million (Q3 2025), and $4.9 million (Q2 2025).